Day: May 6, 2020

ISLAND PARK, N.Y., May 06, 2020 (GLOBE NEWSWIRE) — Global Diversified Marketing Group Inc (OTC: GDMK) announced it has signed an agreement with Asian American Trade Associations Council (AATAC) to expand one of its premier brands, Biscottelli, at select AATAC’s member retailers including branded locations such as Hess, Mobil, 76, Gulf, Chevron, BP, Sunoco, Circle K, 7-Eleven and other gas stations and convenience stores (C-Stores) throughout the United States.The rollout of Biscottelli Croissants will launch in the Northeast (8494 members) & Southeast (20,436 members) regions and eventually covering two other regions, Mid-West & West Coast, which will reach most of the United States with another (31,123 members). AATAC has 60,053 members controlling over 80,000 locations. The target goal is 1,500 to 2,500 locations a month...

BASKING RIDGE, N.J., May 06, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced it will present full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions (“SCAI”) 2020 Scientific Sessions Virtual Conference being held virtually May 13-16, 2020.Oral presentation details:The ESCaPE-CMD1 trial was an interventional, proof-of-concept study designed to evaluate the ability of Caladrius’s autologous CD34+ cell therapy (CLBS16) to reverse the underlying pathology of CMD, the loss of microcirculation, and thereby alleviate symptoms. The key...

MIAMI , May 06, 2020 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 second quarter ended March 31, 2020, on Wednesday, May 13, 2020 before the market opens.  Veru’s management will host a conference call that same day at 8 a.m. ET to review the Company’s performance and to answer questions.  The call will also be accessible via webcast.Event DetailsInterested parties may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call.  The call will also be available through a live, listen-only audio broadcast via the Internet at www.verupharma.com.  Listeners...

MINNEAPOLIS, May 06, 2020 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter, entered the race to develop a COVID-19 vaccine.  The groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein) which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things.  The ferritin platform is currently exploited by NIH in its exploration of the universal flu vaccine which completed phase I clinical trials earlier this year and...

REVENUE INCREASE OF 18% TO $44.2 MILLIONNET INCOME INCREASED 127% TO $1.5 MILLION, $0.15 PER BASIC SHARESTRONG BOOKINGS, WITH BOOK TO BILL RATIO OF 1.5:1NEWARK, N.Y., May 06, 2020 (GLOBE NEWSWIRE) — IEC Electronics Corp. (Nasdaq: IEC) today announced results for the fiscal 2020 second quarter and six months ended March 27, 2020.IEC reported revenues of $44.2 million for the second quarter of fiscal 2020, an increase of 18.4% as compared to revenues of $37.3 million for the second quarter of the year ended September 30, 2019 (“fiscal 2019”).  Gross profit for the second quarter of fiscal 2020 was $5.5 million, or 12.5% of sales, compared to gross profit of $4.6 million, or 12.3% of sales in the second quarter of fiscal 2019.  Selling and administrative expenses were $3.2 million in the second quarter of fiscal 2020, or 7.3% of sales,...

TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally licensed producer and distributor of medical-grade cannabis, is pleased to announce that Angelo Tsebelis, Chief Executive Officer and Stephen Ng, Chief Commercial Officer, will be presenting in Canaccord Genuity’s 4th Annual Global Cannabis Virtual Conference on Tuesday, May 12, 2020 at 8:40 a.m. Eastern Time.The conference will be held via webcast and a presentation link will be provided on WeedMD’s Investor Events page closer to the date.Canaccord Genuity’s Annual Global Cannabis Conference is an investor-focused virtual event that engages a global network of leading players in the cannabis industry. For more information regarding the conference and to schedule a one-on-one meeting with WeedMD, please...

BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary...

TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, and Aragen Bioscience, a leading contract research organization (CRO) focused on accelerating pre-clinical biologics product development, today announced a co-marketing agreement that will provide clients an integrated “sequence-to-manufacturing” service.  Under terms of the non-exclusive agreement, the companies will offer customers Aragen’s cell line development expertise integrated with Avid’s upstream and downstream process development and analytical services to drive efficiencies...

– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth hormone deficiency diagnostic –– Planned safety and efficacy study AEZS-130-P02 (“Study P02”) of macimorelin expected to commence in Q4 2020 –– Advancing ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and other key global markets –CHARLESTON, S.C., May 06, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today reported its financial and operating results for the three months ended March 31, 2020.The Company also provided an...

The following is an extract from the “CNH Industrial 2020 first quarter results” press release. The complete press release can be accessed by visiting the media section of the CNH Industrial corporate website: https://www.cnhindustrial.com/en-us/media/press_releases/Pages/default.aspx or consulting the accompanying PDF:CNH Industrial reports 2020 first quarter Consolidated revenues of $5.5 billion,Net loss of $54 million and Net debt of Industrial Activities at $2.3 billion.Available liquidity at $9.9 billion as of March 31, 2020Financial results presented under U.S. GAAPCONSOLIDATED RESULTSConsolidated revenues of $5.5 billion in the first quarter of 2020, down 15% compared to the first quarter of 2019 (down 13% at constant currency)Net loss of $54 million (or $0.05 loss per share) in the first quarter of 2020 compared to net income...